Norovirus
3
Pipeline Programs
2
Companies
3
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
2
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Vaccine
2100%
+ 1 programs with unclassified modality
Competitive Landscape
2 companies ranked by most advanced pipeline stage
TakedaTOKYO, Japan
2 programs2
NoV GI.1/GII.4 Bivalent VLP VaccinePhase 2Vaccine1 trial
Norovirus GI.1/GII.4 Bivalent VLP VaccinePhase 2Vaccine1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
TakedaNorovirus GI.1/GII.4 Bivalent VLP Vaccine
TakedaNoV GI.1/GII.4 Bivalent VLP Vaccine
Cocrystal PharmaCDI-988
Clinical Trials (3)
Total enrollment: 370 patients across 3 trials
Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine in an Elderly Population
Start: Feb 2016Est. completion: Sep 2017320 patients
Phase 2Completed
Serologic Assay Validation, Proficiency Testing, Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine
Start: Feb 2015Est. completion: Sep 201550 patients
Phase 2Completed
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CDI-988 in Healthy Adults After Challenge With Snow Mountain Virus
Start: Mar 2026Est. completion: Dec 2026
Phase 1/2Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 370 patients
Vaccine is the dominant modality (100% of programs)
2 companies competing in this space